Change Password!
Reset Password!
Dr. Reddy’s has partnered with Takeda to launch Vonoprazan (VONO™), a novel acid blocker enhancing its GI treatment offerings in India.
According to a recent press release, Dr Reddy’s Laboratories Ltd. has signed a non-exclusive patent licensing agreement with Takeda to introduce Vonoprazan in India. Vonoprazan, a novel potassium competitive acid blocker (PCAB), will be marketed under the trademark VONO™ in 10mg and 20mg doses.
Building on its long history of trusted GI products, such as Omeprazole and Rabeprazole, this move, supported by a licensing agreement with Takeda, aimed to enhance patient care through innovative treatments.
Vonoprazan is a groundbreaking potassium competitive acid blocker (PCAB) that works by inhibiting the proton pump’s potassium exchange, leading to effective and sustained acid suppression. Unlike conventional proton pump inhibitors (PPIs), Vonoprazan offers immediate and complete acid control, making it a valuable option for patients with complex gastrointestinal conditions.
The licensing agreement allows Dr Reddy to use its extensive market presence to make Vonoprazan available, leveraging its established reputation in gastrointestinal treatments.
Dr Reddy’s Press Release
https://www.drreddys.com/cms/cms/sites/default/files/2024-07/Dr.%20Reddy%27s%20and%20Takeda.pdf
Dr. Reddy’s signs non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan, a novel gastrointestinal drug, in India
Comments (0)